Hints and tips:
Related Special Reports
...Shares in Pfizer, which developed a vaccine and an antiviral drug, have plummeted 46 per cent from their peak in late 2021, while its German vaccine partner BioNTech is down 75 per cent and rival Moderna...
...That is problematic given the amount of contested information and conspiracy theories about medicine and health services that is posted online, for example by members of the “anti-vaccine” movement....
...Health authorities had also hoped it could help sway sceptics who preferred not to receive an mRNA vaccine, though demand has since collapsed....
...Contracts were concluded with eight vaccine developers, providing as many as 4.2bn doses....
...Novavax was “committed” to continuing to deliver its vaccine, she added....
...“Potentially, this is much broader than Covid vaccines or vaccines in general.”...
...Valued at more than $40bn at the height of the pandemic in early 2021, Novavax made a series of mis-steps with the launch of its Covid vaccine....
...focused Novartis”....
...BioNTech has written down about €900mn on its Covid-19 vaccines because of lower than expected demand for the shots it developed with partner Pfizer....
...Mentioned in this podcast: Tesla shareholders braced for worst results in 7 years Why oil prices remain steady even as Middle East tensions escalate Covid vaccine makers to clash in London over mRNA patent...
...A group of Wall Street traders maliciously drove down the share price of a Maryland biotech with a promising new brain cancer vaccine, in pursuit of the marginal profits to be made by buying the stock cheaply...
...However, she has since struggled with weakening vaccine demand, rising retail competition and wavering consumer spending, which have also weighed on rival CVS Health....
...Sales of Covid-19 vaccines have been falling as governments work through existing supplies and contracts, and fewer people take up annual boosters....
...The FDA on Monday said Covid-19 vaccines “may need to be updated annually, as is done for the seasonal influenza vaccine”, unless a “markedly more virulent variant” emerges, which could require swifter action...
...Pharmaceuticals groups Pfizer and Moderna, which have both faced criticism from fringe groups over their Covid-19 vaccines, also spent heavily on security for their CEOs last year....
...The company also faces a $700mn arbitration process linked to its cancellation of a vaccine contract with Gavi, an international body providing vaccines to poor countries....
...“I began to change my mind around 2020 with the new mRNA vaccines and computational biology,” Cowen tells me. “Then AI came along....
...Novavax’s vaccine, which uses a traditional type of technology, has been widely approved and had been seen as a desirable alternative for vaccine sceptics who preferred not to receive messenger RNA, or mRNA...
...Revenue for Pfizer’s Comirnaty vaccine and Paxlovid, an oral treatment, are expected to generate just $8bn in 2024. That compares with $57bn in 2022 and a forecast of $12.5bn for 2023....
...After raking in billions of dollars through sales of the Covid vaccine it co-developed with Germany’s BioNTech during the pandemic and seeing share prices surge, Pfizer has struggled to reorientate its pipeline...
...Founded by the Sandoz family, the business merged with Ciba-Geigy to create Novartis in 1996....
...As the rollout of bivalent boosters for Covid-19 continues, experts are concerned that the US isn’t doing enough to support the development of the next wave of vaccines and treatments that the world needs...
...Crisis at Hargreaves Lansdown In November 2020, a frenzy of trading among retail investors rushed to cash in on a sharp market rally triggered by positive Covid-19 vaccine news....
...Bauman said the vaccine stimulated a person’s immune system to selectively target those cancer cells....
...The UK regulator was the first in the world to approve an mRNA vaccine for Covid-19. But since the pandemic, it has been criticised for falling behind and causing delays for commercial clinical trials....
International Edition